natgillin/translations-raw huggingface dataset:
The instructions on how to inject yourself are at the end of this leaflet (see section 7, How to inject AVONEX PEN).
Navodila za samoinjiciranje zdravila so na koncu tega navodila (glejte poglavje 7, Kako injicirati zdravilo z napolnjenim injekcijskim peresnikom AVONEX PEN).
The insulin degludec glucose-lowering action at steady state shows four times lower day-to-day variability in terms of Coefficients of Variation (CV) for the glucose-lowering effect during
V primerjavi z insulinom glargin je zniževanje koncentracije glukoze z insulinom degludek v stanju dinamičnega ravnovesja štirikrat manj variabilno, izraženo s koeficientom spremenljivosti (CV)
The insulin dose may need to be adjusted or discontinued in case of remission of the diabetic state.
Odmerek insulina bo morda treba prilagoditi ali uporabo prekiniti pri mačkah z remisijo sladkorne bolezni.
The Insulin Human Winthrop Basal cartridges should only be used with the following pens:
Vložki zdravila Insulin Human Winthrop Basal se lahko uporabljajo samo s sledečimi injekcijskimi peresniki:
The Insulin Human Winthrop range is comprised of fast-acting insulin solutions (Insulin Human Winthrop Rapid and Insulin Human Winthrop Infusat) that contain soluble insulin, an intermediate-acting insulin suspension (Insulin Human Winthrop Basal) that contains isophane insulin, and combinations of fast- and intermediate- acting in various proportions (Insulin Human Winthrop Comb):
Paleta izdelkov Insulin Human Winthrop vključuje raztopine insulinov s hitrim delovanjem (Insulin Human Winthrop Rapid in Insulin Human Winthrop Infusat), ki vsebujejo topni insulin, suspenzije insulinov s srednje dolgim delovanjem (Insulin Human Winthrop Basal), ki vsebujejo insulin izofan, ter kombinacije insulina s hitrim in srednje dolgim delovanjem v različnih razmerjih (Insulin Human Winthrop Comb):
The Insulin Human Winthrop Rapid cartridges should only be used with the following pens:
Vložki zdravila Insulin Human Winthrop Rapid se lahko uporabljajo samo s sledečimi injekcijskimi peresniki:
The insulin in Exubera is produced by a method known as ‘recombinant DNA technology’ which means that the insulin is made by a bacterium which has received a gene (DNA) that makes it able to produce the insulin.
Insulin v zdravilu Exubera je izdelan z metodo, imenovano ‘tehnologija rekombinantne DNA’, kar pomeni, da insulin izdeluje bakterija, ki je prejela gen (DNA), ki ji omogoča izdelovanje insulina.
The insulin lispro in Humalog BASAL is available in a suspension together with protamine sulphate, so that its action is prolonged.
Insulin lispro v zdravilu Humalog BASAL je na voljo v obliki suspenzije skupaj s protamin sulfatom, tako da je njegovo delovanje podaljšano.
The insulin lispro in Humalog BASAL is available in a suspension together with protamine sulphate.
Insulin lispro v zdravilu Humalog BASAL je na voljo v obliki suspenzije skupaj s protamin sulfatom.
The insulin lispro in Humalog BASAL KwikPen is available in a suspension together with protamine sulphate, so that its action is prolonged.
Insulin lispro v zdravilu Humalog BASAL KwikPen je na voljo v obliki suspenzije skupaj s protamin sulfatom, tako da je njegovo delovanje podaljšano.
The insulin lispro in Liprolog Basal is available in a suspension together with protamine sulphate, so that its action is prolonged.
Insulin lispro v zdravilu Liprolog Basal je na voljo v obliki suspenzije skupaj s protamin sulfatom, tako da je njegovo delovanje podaljšano.
The insulin lispro in Liprolog Basal is available in a suspension together with protamine sulphate.
Insulin lispro v zdravilu Liprolog Basal je na voljo v obliki suspenzije skupaj s protamin sulfatom.
The insulin lispro in Liprolog Basal KwikPen is available in a suspension together with protamine sulphate, so that its action is prolonged.
Insulin lispro v zdravilu Liprolog Basal KwikPen je na voljo v obliki suspenzije skupaj s protamin sulfatom, tako da je njegovo delovanje podaljšano.
The insulin lispro solution for injection containing 200 units/ml must not be transferred from the pre- filled pen, the KwikPen, to a syringe.
Raztopine insulina lispro za injiciranje, ki vsebuje 200 enot/ml, se ne sme prenašati iz napolnjenega injekcijskega peresnika KwikPen v brizgo.
The Insulin Release Unit (IRU) should be replaced once every 2 weeks.
Nastavek za sproščanje insulina (Insulin release unit - IRU) je treba zamenjati enkrat na 2 tedna.
The insulin scale shows you approximately how much insulin is left in your pen.
Na merilu preostanka insulina lahko vidite, približno koliko insulina je še ostalo v injekcijskem peresniku.
The insulin should be mixed by turning OptiSet slowly up and down at least 10 times.
Insulin je treba premešati tako, da OptiSet vsaj 10-krat počasi obrne navzgor in navzdol.
The insulin should look evenly mixed.
Insulin mora izgledati enakomerno premešan.
The insulin solution (Insulin Human Winthrop Rapid) must be clear, colourless, with no solid particles visible, and must have a water-like consistency.
Raztopina insulina (Insulin Human Winthrop Rapid) mora biti bistra, brezbarvna, brez vidnih trdnih delcev in vodi podobne konsistence.
The insulin solution (Insuman Rapid) must be clear, colourless, with no solid particles visible, and must have a water-like consistency.
Raztopina insulina (Insuman Rapid) mora biti bistra, brezbarvna, brez vidnih trdnih delcev in vodi podobne konsistence.
The insulin solution must be then degassed according to the degassing procedure described in the Physician’s manual.
Raztopino insulina je treba razpliniti skladno s postopkom za razplinjenje, opisanim v priročniku za zdravnika.
The insulin suspensions (Insulin Human Winthrop Basal or Insulin Human Winthrop mixtures) should be mixed by turning SoloStar up and down at least 10 times to resuspend the insulin.
Suspenzije insulina (Insulin Human Winthrop Basal ali mešanice zdravila Insulin Human Winthrop) naj pretrese z obračanjem SoloStarja gor in dol vsaj 10-krat, tako da insulin ponovno suspendira.
The insulin suspensions (Insuman Basal or Insuman mixtures) should be mixed by turning SoloStar up and down at least 10 times to resuspend the insulin.
Suspenzije insulina (Insuman Basal ali mešanice zdravila Insuman) naj pretrese z obračanjem SoloStarja gor in dol vsaj 10-krat, tako da insulin ponovno suspendira.
The Insuman Basal cartridges are to be used only in conjunction with the pens: OptiPen, ClikSTAR, Autopen 24, Tactipen, AllStar or JuniorSTAR (see section 4.4).
Vložki zdravila Insuman Basal se uporabljajo samo skupaj z injekcijskimi peresniki OptiPen, ClikSTAR, Autopen 24, Tactipen,AllStar ali JuniorSTAR (glejte poglavje 4.4).
The Insuman Basal cartridges are to be used only with the pens: OptiPen, ClikSTAR, Tactipen, Autopen 24, AllStar, JuniorSTAR.
Vložki zdravila Insuman Basal se uporabljajo samo z injekcijskimi peresniki OptiPen, ClikSTAR, Tactipen, Autopen 24, AllStar, JuniorSTAR.
The Insuman Basal cartridges should only be used with the following pens:
Vložki zdravila Insuman Basal se lahko uporabljajo samo s sledečimi injekcijskimi peresniki:
The Insuman Com 15 cartridges should only be used with the following pens:
Vložki zdravila Insuman Comb 15 se lahko uporabljajo samo s sledečimi injekcijskimi peresniki:
The Insuman Comb 15 cartridges are to be used only in conjunction with the pens: OptiPen, ClikSTAR, Autopen 24, Tactipen, AllStar or JuniorSTAR (see section 4.4).
Vložki zdravila Insuman Comb 15 se uporabljajo samo skupaj z injekcijskimi peresniki OptiPen, ClikSTAR, Autopen 24, Tactipen,AllStar ali JuniorSTAR (glejte poglavje 4.4).
The Insuman Comb 15 cartridges are to be used only with the pens: OptiPen, ClikSTAR, Tactipen, Autopen 24, AllStar, JuniorSTAR.
Vložki zdravila Insuman Comb 15 se uporabljajo samo z injekcijskimi peresniki OptiPen, ClikSTAR, Tactipen, Autopen 24, AllStar, JuniorSTAR.
The Insuman Comb 25 cartridges are to be used only in conjunction with the pens: OptiPen, ClikSTAR, Autopen 24, Tactipen, AllStar or JuniorSTAR (see section 4.4).
Vložki zdravila Insuman Comb 25 se uporabljajo samo skupaj z injekcijskimi peresniki: OptiPen, ClikSTAR, Autopen 24, Tactipen, AllStar ali JuniorSTAR(glejte poglavje 4.4).
The Insuman Comb 25 cartridges are to be used only with the pens: OptiPen, ClikSTAR, Tactipen, Autopen 24, AllStar, JuniorSTAR.
Vložki zdravila Insuman Comb 25 se uporabljajo samo z injekcijskimi peresniki OptiPen, ClikSTAR, Tactipen, Autopen 24, AllStar, JuniorSTAR.
The Insuman Comb 25 cartridges should only be used with the following pens:
Vložki zdravila Insuman Comb 25 se lahko uporabljajo samo s sledečimi injekcijskimi peresniki:
The Insuman Comb 30 cartridges are to be used only in conjunction with the pens: OptiPen, ClikSTAR, Autopen 24, Tactipen, AllStar or JuniorSTAR (see section 4.4).
Vložki zdravila Insuman Comb 30 se uporabljajo samo skupaj z injekcijskimi peresniki OptiPen, ClikSTAR, Autopen 24, Tactipen,AllStar ali JuniorSTAR (glejte poglavje 4.4).
The Insuman Comb 30 cartridges are to be used only with the pens: OptiPen, ClikSTAR, Tactipen, Autopen 24, AllStar, JuniorSTAR.
Vložki zdravila Insuman Comb 30 se uporabljajo samo z injekcijskimi peresniki: OptiPen, ClikSTAR, Tactipen,Autopen 24, AllStar, JuniorSTAR.
The Insuman Comb 30 cartridges should only be used with the following pens:
Vložki zdravila Insuman Comb 30 se lahko uporabljajo samo s sledečimi injekcijskimi peresniki:
The Insuman comb 50 cartridges are to be used only in conjunction with the pens: OptiPen, ClikSTAR, Autopen 24, Tactipen, AllStar or JuniorSTAR (see section 4.4).
Vložki zdravila Insuman Comb 50 se uporabljajo samo skupaj z injekcijskimi peresniki OptiPen, ClikSTAR, Autopen 24, Tactipen,AllStar ali JuniorSTAR (glejte poglavje 4.4).
The Insuman Comb 50 cartridges are to be used only with the pens: OptiPen, ClikSTAR, Tactipen, Autopen 24, AllStar, JuniorSTAR.
Vložki zdravila Insulin Comb 50 se uporabljajo samo z injekcijskimi peresniki OptiPen, ClikSTAR, Tactipen, Autopen 24, AllStar, JuniorSTAR.
The Insuman Comb 50 cartridges should only be used with the following pens:
Vložki zdravila Insuman Comb 50 se lahko uporabljajo samo s sledečimi injekcijskimi peresniki:
The Insuman Rapid cartridges are to be used only in conjunction with the pens: OptiPen, ClikSTAR, Autopen 24, Tactipen, AllStar or JuniorSTAR (see section 4.4).
Vložki zdravila Insuman Rapid se uporabljajo samo skupaj z injekcijskimi peresniki OptiPen, ClikSTAR, Autopen 24, Tactipen, AllStar ali JuniorSTAR (glejte poglavje 4.4).
The Insuman Rapid cartridges are to be used only with the pens: OptiPen, ClikSTAR, Tactipen, Autopen 24, AllStar, JuniorSTAR.
Vložki zdravila Insuman Rapid se uporabljajo samo z injekcijskimi peresniki OptiPen, ClikSTAR, Autopen 24, Tactipen, AllStar, JuniorSTAR.
The Insuman Rapid cartridges should only be used with the following pens:
Vložki zdravila Insuman Rapid se lahko uporabljajo samo s sledečimi injekcijskimi peresniki:
The intake of a single bait is sufficient to ensure active immunisation to prevent infection by rabies virus.
Za zagotovitev aktivne imunizacije da se prepreči okužba z virusom stekline zadostuje zaužitje ene same cepilne vabe.
The intake of a single bait is sufficient to ensure active immunisation to prevent infection by rabies virus.
Zaužitje ene same cepilne vabe zadostuje za zaščito lisice/rakunastega psa proti steklini.
The intake of medicated water depends on the clinical condition of the animals.
Uživanje vode s primešanim zdravilom je odvisno od kliničnega stanja živali.
The intake of St John’s Wort should be restricted during the treatment with ivabradine.
Uživanje šentjanževke morate med zdravljenjem z ivabradinom omejiti.
The intended dose of 1.5 g/kg of PegIntron to be used in combination with ribavirin may be delivered in weight categories with the PegIntron strengths according to Table 1.
Za načrtovanje odmerka zdravila PegIntron 1,5 µg/kg za uporabo v kombinaciji z ribavirinom je lahko v pomoč preglednica 1 s kategorijami glede na telesno maso oz. jakost zdravila PegIntron.
The intended therapy was 6 months dabigatran etexilate 150 mg twice daily without need for monitoring.
18-mesečno zdravljenje z antagonisti vitamina K. Predvideno zdravljenje je bilo 6 mesecev jemanja dabigatran eteksilata po 150 mg dvakrat na dan brez spremljanja.
The intensity of the reflected signal is dependent on concentration of the microbubbles and frequency of the ultrasound beam.
Intenziteta odbitega signala je odvisna od koncentracije mikromehurčkov in ultrazvočne frekvence.
The inter-patient variability in a steady-state study in Alzheimer’s dementia was at most 45% (Cmax) and 43% (AUC0-24h) after use of the transdermal patch, and 71% and 73%, respectively, after administration of the oral form.
Interindividualna variabilnost v študiji dinamičnega ravnovesja pri bolnikih z Alzheimerjevo demenco je bila največ 45 % za Cmax in 43 % za AUC0-24h po uporabi transdermalnega obliža v primerjavi z 71 % za Cmax in 73 % za AUC0-24h po aplikaciji peroralne oblike.
The inter-patient variability in a steady-state study in Alzheimer’s dementia was at most 45% (Cmax) and 43% (AUC0-24h) after use of the transdermal patch, and 71% and 73%, respectively, after administration of the oral form.
Interindividualna variabilnost v študiji dinamičnega ravnovesja pri bolnikih z Alzheimerjevo demenco je bila največ 45% za Cmax in 43% za AUC0-24h po uporabi transdermalnega obliža v primerjavi z 71% za Cmax in 73% za AUC0-24h po aplikaciji peroralne oblike.
The interaction between rilpivirine and the medicinal product was evaluated in a clinical study.
Medsebojno delovanje med rilpivirinom in tem zdravilom so ocenjevali v klinični študiji.
The interaction data is presented as geometric mean value with 90% confidence interval (90 % CI) whenever these data were available.
Podatki o interakcijah so povsod, kjer so bili dosegljivi, navedeni kot geometrične srednje vrednosti z 90-odstotnim intervalom zaupanja (90-odstotni IZ).
The interaction of dronedarone on calcium antagonists is described above (see section 4.4).
Medsebojna delovanja dronedarona s kalcijevimi antagonisti so opisana zgoraj (glejte poglavje 4.4).
The interaction of higher doses of caspofungin with other medicinal products has not been formally studied.
Interakcij med večjimi odmerki kaspofungina in drugimi zdravili uradno niso raziskovali.
The interaction potential of dalbavancin on medicinal products metabolised by CYP enzymes is expected to be low since it is neither an inhibitor nor an inducer of CYP enzymes in vitro.
Pričakovana je majhna verjetnost interakcije dalbavancina z zdravili, ki se presnavljajo z encimi CYP, saj ni niti inhibitor niti induktor encimov CYP in vitro.
The interaction profile of Aptivus, co-administered with low dose ritonavir, is complex and requires special attention in particular in combination with other antiretroviral agents.
Profil medsebojnega delovanja zdravila Aptivus, ob hkratnih majhnih odmerkih ritonavirja, je kompleksen, zato moramo biti posebno pozorni, zlasti pri kombinaciji z drugimi protiretrovirusnimi
The interaction profiles of HIV-protease inhibitors, co-administered with low dose ritonavir, are dependant on the specific co-administered protease inhibitor.
Značilnosti medsebojnega delovanja zaviralcev proteaz HIV, uporabljenih sočasno z majhnimi odmerki ritonavirja, so odvisne od specifičnega sočasno uporabljenega zaviralca proteaz.
The interaction profiles of HIV-protease inhibitors, co-administered with low dose ritonavir, are dependent on the specific co-administered protease inhibitor.
Značilnosti medsebojnega delovanja zaviralcev proteaz HIV, uporabljenih sočasno z majhnimi odmerki ritonavirja, so odvisne od specifičnega sočasno uporabljenega zaviralca proteaz.
The interaction trial showed a comparable daily systemic exposure for rifabutin between treatment at 300 mg once daily alone and 150 mg once every other day in combination with PREZISTA/ritonavir (600/100 mg twice daily) with an about 10-fold increase in the daily exposure to the active metabolite
Preskušanje medsebojnih delovanj je pokazalo primerljivo sistemsko izpostavljenost rifabutinu pri zdravljenju samo s 300 mg rifabutina enkrat na dan in pri zdravljenju s 150 mg rifabutina vsak drugi dan v kombinaciji z zdravili PREZISTA/ritonavir (600/100 mg dvakrat na dan).
The interaction with CYP2D6 inhibitors was not tested clinically.
Interakcije z zaviralci encima CYP2D6 klinično niso preskusili.
The interaction with midazolam lacks clinical relevance, and therefore no dose adjustment is needed for CYP3A4 substrates.
Medsebojno delovanje z midazolamom ni klinično pomembno, zato prilagajanje odmerkov substratov CYP3A4. ni potrebno.
The interactions described are based on studies conducted with Genvoya, or the components of Genvoya (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide), as individual agents and/or in combination, or are potential drug-drug interactions that may occur with Genvoya.
Opisane interakcije temeljijo na študijah, izvedenih z zdravilom Genvoya ali z učinkovinami zdravila Genvoya (elvitegravir, kobicistat, emtricitabin in alafenamidtenofovirat), kot posamičnimi učinkovinami in/ali v kombinaciji, ali pa je možno medsebojno delovanje, ki se lahko pojavi z zdravilom Genvoya.
The Interactions section of the SPC for ritonavir should also be consulted for information about potential interactions.
Treba je upoštevati informacije o možnem medsebojnem delovanju zdravil, ki jih najdemo v poglavju o medsebojnem delovanju z drugimi zdravili v Povzetku glavnih značilnosti zdravila za ritonavir.
The interface between the sulphur hexafluoride bubble and the aqueous medium acts as a reflector of the ultrasound beam thus enhancing blood echogenicity and increasing contrast between the blood and the surrounding tissues.
Mejna ploskev med mehurčkom žveplovega heksafluorida in vodnim medijem deluje kot odbojnik ultrazvočnih valov in tako poveča ehogenost krvi in poveča kontrast med krvjo in okoliškimi tkivi.
The interference mitigation methods include treating reagent RBCs with dithiothreitol (DTT) to disrupt daratumumab binding or other locally validated methods.
Med metode, s katerimi je mogoče zmanjšati vpliv daratumumaba, sodijo obdelava reagentnih eritrocitov z ditiotretiolom (DTT) (kar onemogoči vezavo daratumumaba), ali druge lokalno validirane metode.
The interferon alfa-2b in IntronA is produced by a method known as ‘recombinant DNA technology’: it is made by a bacterium that has received a gene (DNA), which makes it able to produce interferon alfa-2b.
Interferon alfa-2b, ki ga vsebuje zdravilo IntronA, se proizvaja po metodi, znani kot „tehnologija rekombinantne DNK“: pri kateri bakterija prejme gen (DNK), s katerim lahko tvori interferon alfa-2b.
The interferon beta-1b is made by a bacterium that has received a gene (DNA), which makes it able to produce it.
Interferon beta-1b proizvajajo z metodo, imenovano „tehnologija rekombinantne DNK“, pri kateri bakterija prejme gen (DNK), s katerim lahko tvori ta interferon.
The interferon in Plegridy is produced by a method known as ‘recombinant DNA technology’.
Interferon v zdravilu Plegridy se pridobiva z metodo, imenovano „tehnologija rekombinantne DNK“.
The interim OS analysis did not meet the protocol-specified early stopping boundary for OS (p ≤ 0.014).
Vmesna analiza celokupnega preživetja (OS) ni izpolnjevala s protokolom določene meje zgodnje prekinitve za OS (p ≤ 0,014).
The interim reports will be submitted every two years until the final patient is followed for 5 years.
Vmesna poročila bodo predložena vsaki 2 leti, dokler ne bo zadnji bolnik spremljan 5 let.
The interval between each injection should be at least 1 month.
Presledek med injekcijama mora biti vsaj 1 mesec.
The interval between each injection should be at least 1 month.
Presledka med injekcijami morata biti vsaj po 1 mesec.
The interval between each injection should be at least 2 months
Presledek med injekcijama mora biti vsaj 2 meseca.
The interval between each injection should be at least 2 months.
Presledek med injekcijama mora biti vsaj 2 meseca.
The interval between the injections should be at least 2 months.
Presledek med injekcijama mora biti vsaj 2 meseca.
The interval between the last maintenance dose and the first re- induction dose ranged from 35-231 days.
Časovni razmik med zadnjim vzdrževalnim odmerkom zdravila in prvim odmerkom pri ponovni uporabi uvodne sheme je bil od 35 do 231 dni.
The interval between the pneumococcal conjugate vaccine (Prevenar) and the 23- valent pneumococcal polysaccharide vaccine should not be less than 8 weeks.
Presledek med konjugiranim pnevmokoknim cepivom (Prevenar) in 23-valentnim pnevmokoknim polisaharidnim cepivom mora biti najmanj 8 tednov.
The interval between the pneumococcal conjugate vaccine (Prevenar) and the 23- valent pneumococcal polysaccharide vaccine should not be less than 8 weeks.
Presledek med konjugiranim pnevmokoknim cepivom (Prevenar) in 23-valentnim pnevmokoknim polisaharidnim cepivom naj bo najmanj 8 tednov.
The interval between two doses injected into the same eye should be at least four weeks.
Med dvema odmerkoma, injiciranima v isto oko, mora preteči najmanj 4 tedne.
The interval between two doses injected into the same eye should be at least four weeks.
Med injiciranjem dveh odmerkov v isto oko mora preteči najmanj štiri tedne.
The interval between two doses should not be shorter than one month.
Interval med dvema injekcijama ne sme biti krajši od enega meseca.
The interval between two injections of Lucentis into the same eye must be at least four weeks.
Med dvema injekcijama zdravila Lucentis v isto oko mora biti vsaj štiritedenski premor.
The intra-individual variability in time to maximum concentration is significantly less for NovoRapid than for soluble human insulin, whereas the intra- individual variability in Cmax for NovoRapid is larger.
Intraindividualna variabilnost časa do največje koncentracije je pri zdravilu NovoRapid značilno manjša kot pri topnem humanem insulinu, medtem ko je intraindividualna variabilnost Cmax pri zdravilu NovoRapid večja.
The intra-subject coefficients of variation for saxagliptin Cmax and AUC were less than 12 %.
Intraindividualna koeficienta variacije Cmax in AUC saksagliptina sta bila manj kot 12 %.
The intra-subject variability of glucose lowering activity of inhaled human insulin was generally comparable to that of subcutaneously administered fast-acting human insulin in subjects with type 1 and 2 diabetes mellitus.
Variabilnost aktivnosti zniževanja glukoze humanega insulina za inhaliranje je bila na splošno primerljiva s tisto pri subkutano apliciranem hitrodelujočem humanem insulinu pri bolnikih z diabetesom mellitusom tipa 1 in 2.
The intracellular anabolism of 6-merpactopurine is catalysed by several enzymes to eventually form 6-thioguanine nucleotides (TGNs), but a variety of intermediary TGNs are formed en route to the TGNs.
6-merkaptopurina se katalizira z več encimi, ki ga v končni fazi pretvorijo v 6-tiogvanin nukleotide (TGN), vendar se v postopku do oblikovanja končnih TGN oblikuje več vmesnih TGN.
The intranasal dosing of 110 micrograms once daily does not typically result in measurable plasma concentrations (<10 pg/ml).
110 mikrogramov enkrat na dan plazemske koncentracije tipično niso bile merljive (< 10 pg/ml).
The intraperitoneal LD50 in mice was found to be approximately 315 mg/kg.
Ugotovljeno je bilo, da je intraperitonealna LD50 pri miših približno 315 mg/kg.
The intravascular administration of iodinated contrast agents in radiological studies can lead to renal failure which has been associated with lactic acidosis in patients receiving metformin.
Intravaskularna uporaba jodiranih kontrastnih sredstev pri radioloških pregledih lahko povzroči odpoved ledvic, povezano z laktacidozo, pri bolnikih, ki prejemajo metformin.
The intravascular administration of iodinated contrast agents in radiological studies can lead to renal failure which has been associated with lactic acidosis in patients receiving metformin.
Intravaskularna uporaba jodiranih kontrastnih sredstev pri radioloških preiskavah lahko povzroči odpoved ledvic, ki je bila pri prejemnikih metformina povezana z laktacidozo.